(Q46935899)

26 December 2017

title

Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada (English)

1 reference

26 December 2017

0 references

0 references

Micheline Gagnon

1

1 reference

26 December 2017

Benoît Rive

series ordinal

2

1 reference

26 December 2017

Margaret Hux

series ordinal

3

1 reference

26 December 2017

Chantal Guilhaume

series ordinal

4

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

26 December 2017

Canadian Journal of Psychiatry

published in

1 reference

26 December 2017

volume

52

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

page(s)

519-526

1 reference

26 December 2017

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Life expectancy with cognitive impairment in the older population of the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Dementing disorders in the elderly: evolution of disease severity over 7 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Teaching old rats new tricks: age-related impairments in olfactory reversal learning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Predicting time to nursing home care and death in individuals with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Cognitive scores, even within the normal range, predict death and institutionalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care--the LASER-AD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705200810

10.1177/070674370705200810

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017